Your browser doesn't support javascript.
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Montero, Fernando; Martínez-Barrio, Julia; Serrano-Benavente, Belén; González, Teresa; Rivera, Javier; Molina Collada, Juan; Castrejón, Isabel; Álvaro-Gracia, Jose.
  • Montero F; Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain. fernandojose.montero@salud.madrid.org.
  • Martínez-Barrio J; Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.
  • Serrano-Benavente B; Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.
  • González T; Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.
  • Rivera J; Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.
  • Molina Collada J; Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.
  • Castrejón I; Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.
  • Álvaro-Gracia J; Department of Rheumatology. Hospital General, Universitario Gregorio Marañón, 28007, Madrid, Spain.
Rheumatol Int ; 40(10): 1593-1598, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: covidwho-713879
ABSTRACT

OBJECTIVE:

To describe clinical characteristics of patients with rheumatic and musculoskeletal diseases (RMDs) and immunosuppressive therapies with Coronavirus disease 2019 (COVID-19) at an academic rheumatology center in Madrid and to identify baseline variables associated with a severe infection requiring hospitalization.

METHODS:

We identified SARS-CoV-2 positive cases by polymerase chain reaction performed at our center within an updated RMDs database in our clinic. Additional RMDs patients were identified when they contacted the clinic because of a positive infection. Data extraction included diagnosis, demographics, immunosuppressive treatment, comorbidities, and laboratory tests. Comparisons between patients with or without hospitalization were performed. Multivariate logistic regression was used to analyze associations between baseline variables and need for hospitalization.

RESULTS:

A total of 62 patients with COVID-19 and underlying RMDs were identified by April 24, 2020. Median age was 60.9 years, and 42% men. Forty-two patients required hospitalization; these were more frequently men, older and with comorbidities. There were no statistically significant between-group differences for rheumatologic diagnosis and for baseline use of immunosuppressive therapy except for glucocorticoids that were more frequent in hospitalized patients. Total deaths were 10 (16%) patients. In multivariate analysis, male sex (odds ratio [OR], 8.63; p = 0.018), previous lung disease (OR, 27.47; p = 0.042), and glucocorticoids use (> 5 mg/day) (OR, 9.95; p = 0.019) were significantly associated to hospitalization.

CONCLUSION:

Neither specific RMD diagnoses or exposures to DMARDs were associated with increased odds of hospitalization. Being male, previous lung disease and exposure to glucocorticoids were associated with higher odds of hospitalization in RMDs patients.
Asunto(s)
Artritis Psoriásica/tratamiento farmacológico; Artritis Reumatoide/tratamiento farmacológico; Infecciones por Coronavirus/fisiopatología; Glucocorticoides/uso terapéutico; Hospitalización/estadística & datos numéricos; Inmunosupresores/uso terapéutico; Lupus Eritematoso Sistémico/tratamiento farmacológico; Neumonía Viral/fisiopatología; Anciano; Antibacterianos/uso terapéutico; Anticuerpos Monoclonales Humanizados/uso terapéutico; Antirreumáticos/uso terapéutico; Antivirales/uso terapéutico; Artritis Psoriásica/complicaciones; Artritis Psoriásica/epidemiología; Artritis Reumatoide/complicaciones; Artritis Reumatoide/epidemiología; Enfermedades Autoinmunes/complicaciones; Enfermedades Autoinmunes/tratamiento farmacológico; Enfermedades Autoinmunes/epidemiología; Azitromicina/uso terapéutico; Betacoronavirus; COVID-19; Comorbilidad; Infecciones por Coronavirus/complicaciones; Infecciones por Coronavirus/tratamiento farmacológico; Infecciones por Coronavirus/mortalidad; Infecciones por Coronavirus/terapia; Combinación de Medicamentos; Femenino; Humanos; Hidroxicloroquina/uso terapéutico; Modelos Logísticos; Lopinavir/uso terapéutico; Enfermedades Pulmonares/epidemiología; Lupus Eritematoso Sistémico/complicaciones; Lupus Eritematoso Sistémico/epidemiología; Masculino; Persona de Mediana Edad; Análisis Multivariante; Pandemias; Neumonía Viral/complicaciones; Neumonía Viral/mortalidad; Neumonía Viral/terapia; Estudios Retrospectivos; Ritonavir/uso terapéutico; SARS-CoV-2; Índice de Severidad de la Enfermedad; Factores Sexuales; España/epidemiología; Tratamiento Farmacológico de COVID-19
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Artritis Reumatoide / Artritis Psoriásica / Infecciones por Coronavirus / Glucocorticoides / Hospitalización / Inmunosupresores / Lupus Eritematoso Sistémico Tipo de estudio: Estudio observacional / Estudio pronóstico / Revisiones Tópicos: Covid persistente País/Región como asunto: Europa Idioma: Inglés Revista: Rheumatol Int Año: 2020 Tipo del documento: Artículo País de afiliación: S00296-020-04676-4

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Neumonía Viral / Artritis Reumatoide / Artritis Psoriásica / Infecciones por Coronavirus / Glucocorticoides / Hospitalización / Inmunosupresores / Lupus Eritematoso Sistémico Tipo de estudio: Estudio observacional / Estudio pronóstico / Revisiones Tópicos: Covid persistente País/Región como asunto: Europa Idioma: Inglés Revista: Rheumatol Int Año: 2020 Tipo del documento: Artículo País de afiliación: S00296-020-04676-4